Aushon Announces Availability of
Ultrasensitive Cira™ Assays
New Assays Measure Proteins at Femtogram/mL Sensitivity
Billerica, Mass. — June 2, 2015 —
Aushon BioSystems, a leading provider of products and services for multiplex quantitative detection of protein biomarkers, today announced the commercial release of its Ultrasensitive Cira™ Assays capable of measuring concentrations of low abundance proteins down to the femtogram/mL level.
“These new ultrasensitive test kits will enable researchers and clinicians to measure analytes at previously undetectable levels without giving up the precision and ease of use of our Cira™ platform. With total assay time of under three hours and the ability to read an entire 96-well plate in under five minutes, these assays are suitable for use in Iarge clinical studies” said Susan Vogt, CEO of Aushon. “In addition, these assays have a quantitative range of up to five logs, enabling researchers to simultaneously measure both the high and low regions of the range for a single analyte.”
Added Pete Honkanen, Aushon’s founder and COO, “As we’ve continued to advance the performance of our Cira™ platform, we’ve been able to achieve detection levels down to single femtograms. Cira™ is the only platform which combines both the productivity of multiplexed assays with ultrasensitive detection levels. This means researchers no longer have to trade off between throughput and sensitivity. These new assays will enable scientists and clinicians to detect and monitor changes in extremely low levels of established disease biomarkers and gain new insights into diagnostics and therapeutic treatments. The first kits available are assays for human cytokines for which the endogenous levels are known to be low, or are important markers for developers of immunotherapies, including IFNγ, IL-1β, IL-6, IL-10, and TNFα.”
About Aushon BioSystems
Aushon BioSystems, Inc. provides a comprehensive suite of multiplex immunoassay products and services for protein biomarker discovery, development, and analysis to leading pharmaceutical, biotechnology, academic, and diagnostic clients worldwide. Our unique combination of proprietary microarray printing, extensive biomarker content, and innovative Cira™ immunoassay platform delivers exceptional performance, quality, and reliability to accelerate preclinical and clinical biomarker research. Our customers, who include leading pharmaceutical companies and translational research centers, trust Aushon to supply the most reliable biomarker data available, accelerating the evaluation of potential drug candidates and advancing the use of biomarker profiles in therapeutics.
Chief Executive Officer